miltenyibiotec.comEmpty Containers For The Collection & Processing Of Blood/Blood Components
Miltenyi Biotec, Inc.
Miltenyi Biotec Inc
FDA Registration(s)#
| Registration | FEI | Name | Status | Initial importer | Expiration year | Address |
|---|---|---|---|---|---|---|
| 3003348283 | 3003348283 | Miltenyi Biotec Inc | 1 | Y | 2026-01-01 | 2303 Lindbergh St Auburn CA US 95602 |
| 3005290010 | 3004112148 | Miltenyi Biotec B. V. & Co. KG | 1 | N | 2026-01-01 | Friedrich-Ebert-Strasse 68 Bergisch Gladbach North Rhine-Westphalia DE D-51429 |
| 3008264130 | 3008264130 | Miltenyi Biotec B. V. & Co. KG Branch Teterow | 1 | N | 2026-01-01 | Robert-Koch-Strasse 1 Teterow Mecklenburg-Western Pomerania DE D-17166 |
| 3017812890 | 3017812890 | Miltenyi Biotec North America | 1 | Y | 2026-01-01 | 1201 Clopper Road Gaithersburg MD US 20878 |
GUDID Contact Samples#
| Source GUDID | Product | Phone | |
|---|---|---|---|
| 04049934000287 | CryoMACS® Freezing Bag 250 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. | 800-810-3135 | Regulatory_affairs_USA@milteny |
| 04049934000287 | CryoMACS® Freezing Bag 250 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. | 800-810-3135 | Regulatory_affairs_USA@miltenyibiotec.com |
| 04049934000294 | CryoMACS® Freezing Bag 500 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. | 800-810-3135 | Regulatory_affairs_USA@milteny |
| 04049934000294 | CryoMACS® Freezing Bag 500 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. | 800-810-3135 | Regulatory_affairs_USA@miltenyibiotec.com |
Registered Device Listings#
| Registration key | Listing key | Premarket submission |
|---|---|---|
| 114797 | 1871719866 | BK090020 |
| 125742 | 1871719866 | BK090020 |
| 114797 | 1236898861 | BH110018 |
| 125742 | 1236898861 | BH110018 |
| 114797 | 1884933086 | |
| 125742 | 1884933086 |
PMN#
GUDID#
CliniMACS Tubing Set LS - "CliniMACS® Tubing Set (LS) is a single-use, sterile, disposable tubing set with two proprietary cell separation columns used as part of the CliniMACS CD34 Reagent System. The CliniMACS® CD34 Reagent System is an in vitro medical device system used to select and enrich CD34+ cells from HPC, Apheresis while passively depleting other cells, such as CD3+ T cells, which cause graft versus host disease. The system is based on ""magnetically-activated cell sorting"" (MACS) employing antibodies conjugated to iron-containing particles that can be attracted to a magnetic field (referred to as “magnetic labeling”). Using the specificity of anti-CD34 antibody interaction with cell surface CD34 antigen found on hematopoietic progenitor cells, the system enriches CD34+ cells from HPC, Apheresis by passing the antibody-labeled cell suspension through a separation column with a strong magnetic gradient. The separation column retains the magnetically labeled CD34+ target cells while unlabeled cells flow through and are collected in the Negative Fraction Bag. Several automated washing steps are performed, disposing most of the liquid into the Buffer Waste Bag. The magnetically-selected CD34+ cells are released from the separation column when the magnet is disengaged, removing the magnetic field, and the target CD34+ cells are eluted into the Cell Collection Bag."
2015-03-26
CliniMACS Tubing Set TS - "CliniMACS® Tubing Set (TS) is a single-use, sterile, disposable tubing set with two proprietary cell separation columns used as part of the CliniMACS CD34 Reagent System. The CliniMACS® CD34 Reagent System is an in vitro medical device system used to select and enrich CD34+ cells from HPC, Apheresis while passively depleting other cells, such as CD3+ T cells, which cause graft versus host disease. The system is based on ""magnetically-activated cell sorting"" (MACS) employing antibodies conjugated to iron-containing particles that can be attracted to a magnetic field (referred to as “magnetic labeling”). Using the specificity of anti-CD34 antibody interaction with cell surface CD34 antigen found on hematopoietic progenitor cells, the system enriches CD34+ cells from HPC, Apheresis by passing the antibody-labeled cell suspension through a separation column with a strong magnetic gradient. The separation column retains the magnetically labeled CD34+ target cells while unlabeled cells flow through and are collected in the Negative Fraction Bag. Several automated washing steps are performed, disposing most of the liquid into the Buffer Waste Bag. The magnetically-selected CD34+ cells are released from the separation column when the magnet is disengaged, removing the magnetic field, and the target CD34+ cells are eluted into the Cell Collection Bag."
2016-07-22
CliniMACS CD34 Reagent - "CliniMACS® CD34 Reagent is a dark amber, non-viscous, colloidal solution containing an antibody conjugate in buffer. The conjugate consists of a murine IgG1 monoclonal antibody directed against the Class II epitope of the human CD34 antigen, which is chemically conjugated to dextran beads having an iron oxide/hydroxide core used in conjuction with the CliniMACS CD34 Reagent System. The CliniMACS® CD34 Reagent System is an in vitro medical device system used to select and enrich CD34+ cells from HPC, Apheresis while passively depleting other cells, such as CD3+ T cells, which cause graft versus host disease. The system is based on ""magnetically-activated cell sorting"" (MACS) employing antibodies conjugated to iron-containing particles that can be attracted to a magnetic field (referred to as “magnetic labeling”). Using the specificity of anti-CD34 antibody interaction with cell surface CD34 antigen found on hematopoietic progenitor cells, the system enriches CD34+ cells from HPC, Apheresis by passing the antibody-labeled cell suspension through a separation column with a strong magnetic gradient. The separation column retains the magnetically labeled CD34+ target cells while unlabeled cells flow through and are collected in the Negative Fraction Bag. Several automated washing steps are performed, disposing most of the liquid into the Buffer Waste Bag. The magnetically-selected CD34+ cells are released from the separation column when the magnet is disengaged, removing the magnetic field, and the target CD34+ cells are eluted into the Cell Collection Bag."
2015-03-26
CliniMACS Plus Instrument - "The CliniMACS® plus Instrument is a software-controlled instrument that processes the HPC, Apheresis as part of the CliniMACS CD34 Reagent System. The CliniMACS® CD34 Reagent System is an in vitro medical device system used to select and enrich CD34+ cells from HPC, Apheresis while passively depleting other cells, such as CD3+ T cells, which cause graft versus host disease. The system is based on ""magnetically-activated cell sorting"" (MACS) employing antibodies conjugated to iron-containing particles that can be attracted to a magnetic field (referred to as “magnetic labeling”). Using the specificity of anti-CD34 antibody interaction with cell surface CD34 antigen found on hematopoietic progenitor cells, the system enriches CD34+ cells from HPC, Apheresis by passing the antibody-labeled cell suspension through a separation column with a strong magnetic gradient. The separation column retains the magnetically labeled CD34+ target cells while unlabeled cells flow through and are collected in the Negative Fraction Bag. Several automated washing steps are performed, disposing most of the liquid into the Buffer Waste Bag. The magnetically-selected CD34+ cells are released from the separation column when the magnet is disengaged, removing the magnetic field, and the target CD34+ cells are eluted into the Cell Collection Bag."
2015-03-26
CryoMACS® Freezing Bag 1000 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells.
2016-07-22
CryoMACS® Freezing Bag 750 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells.
2016-07-22
CryoMACS® Freezing Bag 500 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells.
2016-07-22
CryoMACS® Freezing Bag 250 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells.
2016-07-22
CryoMACS® Freezing Bag 50 - The CryoMACS® Freezing Bags are single use only, sterile (by irradiation), containers intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells. The CryoMACS® Freezing Bags are comprised of a freezing bag (with access ports) as the primary containment for the hematopoietic progenitor cells and an overwrap bag as secondary containment. They have an integrated tubing set (Filling Assembly) containing an injection port and male and female luer lock assemblies which provide flexibility to use a variety of disposable transfer sets, syringes or Sterile Connecting Device (SCD®) for aseptic processing. Additionally, the CryoMACS® Freezing Bags have a built-in label pocket which allows the insertion of written information such as patient identification and product specifications for hematopoietic progenitor cells, volume and processing methods used. As part of the bag assembly, two spike ports are available which allow access to the bag contents for therapeutic use of the product (via attachment of a sterile transfusion assembly). Intended Use: The CryoMACS® Freezing Bag are intended for a single cycle of freezing, storage (down to -196°C), and subsequent thawing (at 37°C) of hematopoietic progenitor cells.
2017-12-18
CliniMACS PBS/EDTA Buffer 1L - "CliniMACS® PBS/EDTA Buffer is a single-use, sterile, isotonic buffer solution used as part of the CliniMACS CD34 Reagent System. The CliniMACS® CD34 Reagent System is an in vitro medical device system used to select and enrich CD34+ cells from HPC, Apheresis while passively depleting other cells, such as CD3+ T cells, which cause graft versus host disease. The system is based on ""magnetically-activated cell sorting"" (MACS) employing antibodies conjugated to iron-containing particles that can be attracted to a magnetic field (referred to as “magnetic labeling”). Using the specificity of anti-CD34 antibody interaction with cell surface CD34 antigen found on hematopoietic progenitor cells, the system enriches CD34+ cells from HPC, Apheresis by passing the antibody-labeled cell suspension through a separation column with a strong magnetic gradient. The separation column retains the magnetically labeled CD34+ target cells while unlabeled cells flow through and are collected in the Negative Fraction Bag. Several automated washing steps are performed, disposing most of the liquid into the Buffer Waste Bag. The magnetically-selected CD34+ cells are released from the separation column when the magnet is disengaged, removing the magnetic field, and the target CD34+ cells are eluted into the Cell Collection Bag."
2016-07-22
CD10-PE - 97C5 recognizes human CD10, the human common acute lymphoblastic leukemia antigen. CD10 is a 100 kDa cell surface molecule identical to human membrane-associated neutral endopeptidase and also known as neprilysin or enkephalinase. Human CD10 is expressed on a wide variety of normal and neoplastic cell types from different tissues including neural and hematopoietic cells. It is expressed on pre and pro B cells and is involved in B cell development and differentiation. The antigen is also present on mature neutrophils, T cell precursors, and some T cell leukemias or lymphomas. Furthermore, CD10 is expressed on neoplastic cells of several B lymphoid leukemias or lymphomas.
2021-03-26
CD33-PE - AC104.3E3 recognizes the human CD33 antigen, a 67 kDa glycoprotein belonging to the sialoadhesin superfamily. The CD33 antigen is highly expressed on human monocytes but weakly on granulocytes and some - but not all - myeloid dendritic cells. The CD33 antigen is also found on myeloid progenitor cells (CFU-GEMM, CFU GM, CFU-G, BFU-E) but is not expressed on lymphocytes, platelets, erythrocytes, or primitive hematopoietic stem cells.
2021-03-26
CD38-FITC - IB6 recognizes the human CD38 antigen, a single-chain type II transmembrane glycoprotein with enzymatic activity. It is present on the majority of hematopoietic cells, prevalent during early differentiation and activation processes. Terminally differentiated B cells (plasma cells) express CD38 brightly. Furthermore, CD38 is constitutively expressed in several tissues, for example brain, muscle, and kidney.
2021-03-26
CD45RA-APC - T6D11 recognizes the human CD45RA antigen which is expressed on naive CD4+ and CD8+ T cells as well as on CD8+ effector T cells. CD45RA is also present on subsets of B and NK cells as well as on plasmacytoid dendritic cells. The CD45RA antibody recognizes the 220 kDa isoform of the leukocyte common antigen (LCA), a transmembrane tyrosine phosphatase.
2021-03-26
CD185-APC - REA103 recognizes human CD185, which is a 42 kDa G-protein-coupled chemokine receptor and is also known as CXCR5, monocyte-derived receptor 15 (MDR15), or Burkitt lymphoma receptor-1 (BLR1). BLR-1 was originally identified on cells of Burkitt lymphoma and B cells. B cell attracting chemokine 1 (BCA-1), also known as B-lymphocyte chemoattractant (BLC) or CXCL13, is the ligand of CD185. It is further expressed on central memory CD4 T cells, T follicular helper cells, and on a migratory population of skin-derived dendritic cells. Additional information: Clone REA103 displays negligible binding to Fc receptors.
2021-03-26
Anti-TCRa/b-PE (Clone BW242/412) - BW242/412 recognizes the human alpha/beta T cell receptor (TCR). The T cell receptor (TCR) is a heterodimer composed of two transmembrane glycoprotein chains, alpha and beta. Both chains are members of the Ig superfamily and consist of a constant and a polymorphic variable region. The variable region of the TCRalpha/beta is involved in recognition of antigenic peptides presented by the MHC complex of antigen-presenting cells. The Anti-TCRalpha/beta antibody, BW242/412, recognizes a common determinant of the TCRalpha/beta-CD3 complex.
2021-03-26
CD3-APC - BW264/56 is a monoclonal murine IgG2a antibody, which recognizes the human CD3 antigen present on mature human T cells, thymocytes, and a subset of NK cells. CD3 is associated with the T cell receptor (TCR) and is responsible for its signal transduction. The CD3 antigen is a complex of five invariable chains: gamma, delta, epsilon, zeta and eta. The epitope recognized by the antibody is located on the epsilon-chain of the CD3 complex.
2021-03-26
CD4-VioBlue - The antibody VIT4 is a monoclonal murine IgG2a antibody, which recognizes the human CD4 antigen which is highly expressed on human T helper cells and thymocytes, and at lower levels on monocytes and dendritic cells. It is responsible for the recognition of the MHC Class II antigen.
2021-03-26
CD8-FITC - BW135/80 recognizes the human CD8 antigen which is strongly expressed on human cytotoxic T cells and thymocytes, and is also expressed on a subset of NK cells. The CD8 antigen is a disulfide-linked dimer that exists either as a CD8 alpha homodimer or as a CD8 alpha/beta heterodimer. CD8 acts as a coreceptor for the T cell receptor and binds to the MHC Class I molecule. The CD8 antibody recognizes the alpha-subunit of the antigen.
2021-03-26
CD20-VioBlue - LT20 recognizes the CD20 antigen, a non-glycosylated transmembrane protein of 33–37 kDa that is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca2+ channel and might function in the regulation of local responses during B cell activation.
2021-03-26
CD27-APC - M-T271 recognizes CD27, a member of the tumor necrosis factor receptor family. CD27 is expressed at differing levels on memory B cells, a fraction of plasma cells, and on naive and memory T cells, but is not expressed on naive B cells or effector T cells. It is also expressed on NK cells. CD27 therefore represents a useful marker to distinguish certain T and B cell subsets from each other.
2021-03-26
CD27-FITC - M-T271 recognizes CD27, a member of the tumor necrosis factor receptor family. CD27 is expressed at differing levels on memory B cells, a fraction of plasma cells, and on naive and memory T cells, but is not expressed on naive B cells or effector T cells. It is also expressed on NK cells. CD27 therefore represents a useful marker to distinguish certain T and B cell subsets from each other.
2021-03-26
CD45-VioBlue (Clone 5B1) - 5B1 recognizes the human CD45 antigen, a tyrosine phosphatase also known as the leukocyte common antigen (LCA). The CD45 molecule is required for T and B cell activation and is expressed in at least five isoforms depending on the differentiation status of the cell. The CD45 antibody recognizes a common epitope of all CD45 isoforms.
2021-03-26
CD45-VioGreen (Clone 5B1) - 5B1 recognizes the human CD45 antigen, a tyrosine phosphatase also known as the leukocyte common antigen (LCA). The CD45 molecule is required for T and B cell activation and is expressed in at least five isoforms depending on the differentiation status of the cell. The CD45 antibody recognizes a common epitope of all CD45 isoforms.
2021-03-26
CD56-PE - REA196 recognizes the human CD56 antigen, a glycoprotein of the Ig-superfamily, also known as neural cell adhesion molecule (NCAM), which is expressed in blood on practically all resting and activated NK cells and on a minor subset of CD3+ T cells. CD56 is also expressed in brain (cerebellum and cortex) and at neuromuscular junctions. Certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal-derived tumors, myelomas, and myeloid leukemias also express CD56. Additional information: Clone REA196 displays negligible binding to Fc receptors.
2021-03-26
CD117-PE - A3C6E2 recognizes human CD117, also known as c-kit or SCF receptor. It is a 145 kDa receptor tyrosine kinase that is involved in stem cell signaling, activation, and proliferation. The CD117 antigen is expressed on about 1–3% of mononuclear cells from peripheral blood mononuclear cells (PBMCs) or cord blood, and on up to 10% of bone marrow cells. CD117 is further expressed on basophils, myeloid dendritic cells, TCRa/b+ T cells, CD19+ B cells, and CD56+ NK cells, as well as on mast cells, melanocytes, and AML (acute myeloid leukemia) blasts.
2021-03-26
CD117-APC - A3C6E2 recognizes human CD117, also known as c-kit or SCF receptor. It is a 145 kDa receptor tyrosine kinase that is involved in stem cell signaling, activation, and proliferation. The CD117 antigen is expressed on about 1–3% of mononuclear cells from peripheral blood mononuclear cells (PBMCs) or cord blood, and on up to 10% of bone marrow cells. CD117 is further expressed on basophils, myeloid dendritic cells, TCRa/b+ T cells, CD19+ B cells, and CD56+ NK cells, as well as on mast cells, melanocytes, and AML (acute myeloid leukemia) blasts.
2021-03-26
CD10-APC - 97C5 recognizes human CD10, the human common acute lymphoblastic leukemia antigen (CALLA). CD10 is a 100 kDa cell surface molecule identical to human membrane-associated neutral endopeptidase (NEP) and also known as neprilysin or enkephalinase. Human CD10 is expressed on a wide variety of normal and neoplastic cell types from different tissues including neural and hematopoietic cells. It is expressed on pre– and pro–B cells and is involved in B cell development and differentiation. The antigen is also present on mature neutrophils, T cell precursors, and some T cell leukemias/lymphomas. Furthermore, CD10 is expressed on neoplastic cells of several B lymphoid leukemias/lymphomas.
2021-03-26
CD11b-APC - M1/70.15.11.5 recognizes the human, mouse, and non-human primate CD11b antigen. CD11b, also known as Mac-1 alpha or integrin alphaM chain, is part of the CD11b/CD18 heterodimer (Mac-1 alpha, Mbeta2 integrin), also known as the C3 complement receptor. It functions as a receptor for complement (C3bi), fibrinogen, or clotting factor X. In humans, CD11b is strongly expressed on myeloid cells and weakly expressed on NK cells and some activated lymphocytes as well as on microglia in the brain. In mice, the CD11b antigen is expressed on monocytes/macrophages and microglia. To a lower extent it is expressed on granulocytes, NK cells, CD5+ B-1 cells, and subsets of dendritic cells.
2021-03-26
CD13-PE - REA263 recognizes the CD13 antigen, a 150–170 kDa type II transmembrane glycoprotein, which is also known as aminopeptidase N or gp150. CD13 is expressed on granulocytes, myeloid progenitors, endothelial cells, epithelial cells, and subset of granular lymphoid cells. It is also broadly expressed in other tissues such as kidney proximal tubules, intestine, and placenta. CD13 is an enzyme that is used as a biomarker to detect damage to the kidneys, and that may be used to help diagnose certain kidney disorders. It also serves as a receptor for one strain of human coronavirus that is an important cause of upper respiratory tract infections. Defects in CD13 appear to be a cause of various types of leukemia or lymphoma. Additional information: Clone REA263 displays negligible binding to Fc receptors.
2021-03-26
CD15-FITC - VIMC6 recognizes the human CD15 antigen which is expressed on human myelomonocytic cells. It is present on neutrophils, eosinophils, and some monocytes, masked on basophils but not on lymphocytes. The antigen is also expressed on Hodgkin/Reed-Sternberg cells. The CD15 antibody recognizes the carbohydrate structure 3-fucosyl-N-acetyl-lactosamine. This structure is also known as stage specific embryonic antigen 1 (SSEA-1) and a common surface marker for pluripotency on mouse ES and iPS cells. On human cells in contrast, SSEA-1 is expressed only on early differentiating cells. The CD15 antibody recognizes the SSEA-1 antigen in both species. For applications in ES and iPS research, the dilution recommended in the data sheet may need adjustment.
2021-03-26
CD16-FITC - Clone REA423 recognizes the human CD16 antigen, a single-pass type I membrane protein which is also known as low affinity immunoglobulin gamma Fc region receptor III (FcRIII). CD16 is a 50–80 kDa glycoprotein that is expressed in two different isoforms. The transmembrane form is found on human NK cells, macrophages, and mast cells, while the glycosylphosphatidylinositol (GPI)-linked form is present on neutrophils. The human CD16 antigen is a low-affinity receptor for aggregated IgG. The transmembrane form plays a role in signal transduction, NK cell activation, and antibody-dependent cellular cytotoxicity. Clone REA423 recognizes both the extracellular domain of the transmembrane form as well as the GPI-linked form of the human CD16 antigen. CD16 is expressed on the majority of rhesus monkey NK cells and on a subset of monocytes but not on granulocytes. Additional information: Clone REA423 displays negligible binding to Fc receptors.
2021-03-26
CD21-VioBlue - HB5 recognizes CD21, a type I membrane glycoprotein. Expression of CD21 in humans is found on B cells, follicular dendritic cells, subsets of epithelial cells, and thymic T cells. The primary function attributed to CD21 has been to amplify the B cell receptor (BCR)-mediated signal transduction in response to antigen recognition. To enhance the BCR mediated activation, CD21 associates with CD19 and CD81 in a B cell–specific signal transduction complex, where interaction of BCR with CR2/CD19 amplifies the signals. In addition, CD21 serves as a receptor for split products of complement protein C3, the gp350/220 viral coat protein of the EBV and the immunoregulatory protein CD23.
2021-03-26
CD26-PE - FR10-11G9 recognizes human CD26, a costimulatory molecule that is involved in T cell activation. CD26 is a type II transmembrane protein that acts as an ectoenzyme with prolyl oligopeptidase activity. It is widely expressed in various tissues. In the immune system CD26 is expressed on thymocytes, activated T cells, B cells, NK cells, and macrophages.
2021-03-26
CD33-APC - AC104.3E3 recognizes the human CD33 antigen, a 67 kDa glycoprotein belonging to the sialoadhesin superfamily. The CD33 antigen is highly expressed on human monocytes but weakly on granulocytes and some – but not all – myeloid dendritic cells. The CD33 antigen is also found on myeloid progenitor cells (CFU-GEMM, CFU GM, CFU-G, BFU-E) but is not expressed on lymphocytes, platelets, erythrocytes, or primitive hematopoietic stem cells.
2021-03-26
CD57-FITC - TB03 recognizes the human CD57. CD57, also known as HNK-1 or Leu-7, is an antigenic Oligosaccharide moiety detected on extracellular proteins of certain cell types. In blood, CD57 is found on 15-20% of mononuclear cells, including subsets of NK and T cells, though not on erythrocytes, monocytes, granulocytes, or platelets. Also, CD57 expression can be found on a variety of neural cell types. CD57 has been shown to be expressed on late stage effector CD8+ T cells. The frequency of CD57+ T lymphocytes is raised in a variety of diseases. CD57 expression is also increased on chronically activated CD8+ T cells in persistent viral infections, such as HIV.
2021-03-26
CD62L-FITC - 145/15 recognizes the human CD62L antigen, a 74 kDa glycoprotein and a member of the selectin family of cell surface molecules. CD62L is also known as L-selectin, LECAM-1, or LAM-1 and binds a series of glycoproteins including CD34, GlyCAM-1, and MAdCAM-1. CD62L is important for homing of naive lymphocytes via endothelial venules to peripheral lymph nodes and Peyer’s patches. The CD62L antigen also contributes to the recruitment of leukocytes from the blood to areas of inflammation. Most hematopoietic cells express CD62L, including many peripheral blood B cells, T cells, monocytes, granulocytes, and some myeloid cells from bone marrow, and thymocytes. CD62L is continuously endoproteolytically cleaved from the cell surface neutrophils and lymphocytes (shedding). Proteolysis is accelerated, for example, after antigenic activation of T cells. Always use fresh material for immunofluorescent staining of CD62L+ cells. For optimal results, the cells should not be older than 8–12 hours. Keep cells continuously cold. CD62L-expression may be rapidly lost due to shedding.
2021-03-26
CD2-VioBlue - LT2 recognizes the human CD2 antigen, a 50 kDa single-chain transmembrane glycoprotein also known as LFA-2 or receptor for sheep erythrocytes. CD2 belongs to the Ig superfamily and is involved in cell signaling and lymphocyte adhesion. The CD2 antibody reacts with 80–90 % of peripheral blood lymphocytes and more than 95 % of thymocytes. The antibody recognizes all T cells and a subset of NK cells.
2021-03-26
CD2-FITC - LT2 recognizes the human CD2 antigen, a 50 kDa single-chain transmembrane glycoprotein also known as LFA-2 or receptor for sheep erythrocytes. CD2 belongs to the Ig superfamily and is involved in cell signaling and lymphocyte adhesion. The CD2 antibody reacts with 80–90 % of peripheral blood lymphocytes and more than 95 % of thymocytes. The antibody recognizes all T cells and a subset of NK cells.
2021-03-26
CD25-PE - 4E3 recognizes the human CD25 antigen, a 55 kDa glycoprotein also known as the low-affinity interleukin-2 receptor alpha chain (IL-2Rα). CD25 is expressed on activated T and B cells, on macrophages, and on a subset of non-activated CD4+ regulatory T cells. The CD25 antigen contains three epitope regions called A, B, and C. This CD25 antibody recognizes epitope region B.
2021-03-26